Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer

• Published in: Cancers Vol. 13; no. 18; p. 4651
• Main Authors: Sahin, Katherine B., Shah, Esha T., Ferguson, Genevieve P., Molloy, Christopher, Kalita-de Croft, Priyakshi, Hayes, Sarah A., Hudson, Amanda, Colvin, Emily, Kamitakahara, Hannah, Harvie, Rozelle, Hasovits, Csilla, Khan, Tashbib, Duijf, Pascal H. G., Howell, Viive M., He, Yaowu, Bolderson, Emma, Hooper, John D., Lakhani, Sunil R., Richard, Derek J., O’Byrne, Kenneth J., Adams, Mark N.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 16.09.2021; MDPI
• Subjects: Adenocarcinoma; Antibodies; Biomarkers; Cancer therapies; Casein; Casein kinase II; Cell culture; Cell cycle; Cell division; Chemotherapy; Enzyme inhibitors; Epidermal growth factor; Epidermal growth factor receptors; Kinases; Lung cancer; Mutants; Mutation; Non-small cell lung carcinoma; Patients; Phosphatase; Protein-tyrosine kinase receptors; Proteins; Small cell lung carcinoma; Tumors; Australia

Tyrosine kinase inhibitors (TKIs) are the first-line therapy for non-small-cell lung cancers (NSCLC) that harbour sensitising mutations within the epidermal growth factor receptor (EGFR). However, resistance remains a key issue, with tumour relapse likely to occur. We have previously identified that...